+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Trigeminal Neuralgia Drug"

Trigeminal Neuralgia - Pipeline Insight, 2024 - Product Thumbnail Image

Trigeminal Neuralgia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Trigeminal Neuralgia- Epidemiology Forecast to 2032 - Product Thumbnail Image

Trigeminal Neuralgia- Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Trigeminal Neuralgia (Tic Douloureux) - Global Clinical Trials Review, 2022 - Product Thumbnail Image

Trigeminal Neuralgia (Tic Douloureux) - Global Clinical Trials Review, 2022

  • Clinical Trials
  • February 2022
  • 96 Pages
  • Global
From
From
Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2020 - Product Thumbnail Image

Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 76 Pages
  • Global
From
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Trigeminal Neuralgia (TN) is a chronic pain disorder that affects the trigeminal nerve, one of the largest nerves in the head. It is characterized by episodes of intense, stabbing pain in the face, usually on one side. Treatment for TN typically involves medications, such as anticonvulsants, antidepressants, and muscle relaxants. These drugs are part of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological and psychiatric disorders. The CNS drug market is highly competitive, with many large pharmaceutical companies developing and marketing drugs for the treatment of neurological and psychiatric disorders. Companies such as Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis are some of the major players in the CNS drug market. Other companies, such as Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals, also have a presence in the market. Show Less Read more